Breast Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_7_3391 - Risk-Adapted Postmastectomy Radiation Therapy for Patients with Clinical T1-2N0-1 Breast Cancer after Neoadjuvant Chemotherapy

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Risk-Adapted Postmastectomy Radiation Therapy for Patients with Clinical T1-2N0-1 Breast Cancer after Neoadjuvant Chemotherapy
X. Wang1, Z. Yin2, L. Xu3, Q. Wang4, L. Zhao5, Z. Yuan5, and P. Wang5; 1Tianjin Medical University Cancer Institue and Hospital, Tianjin, China, 2Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, 3Cancer Hospital, Tianjin Medical University, Tianjin, China, 4Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 5Department of Radiation oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention Therapy, Tianjin, China

Purpose/Objective(s): In order to identify risk factors associated with locoregional failure and assess the role of post-mastectomy radiotherapy in early breast cancer (BC) managed with neoadjuvant chemotherapy (NAC) and mastectomy, a retrospective analysis of BC diagnosed with clinical staged T1-2N0-1 were conducted.

Materials/Methods: 217 patients were included in this analysis. The median age was 50 years old (24-72 years old). The clinical stage distribution were cT1 in 15 cases, cT2 in 202 cases, cN0 in 53 cases and cN1 in 161 cases. All patients were treated with NAC and mastectomy, and 128 patients also received postmastectomy radiotherapy (PMRT). The pathological stage distribution as following, 11 cases were p T0, 87 were p T1, 102 were p T2, 9 were p T3 and 8 were p T4; 58 cases were p N0, 61 were p N1, 48 were p N2, 50 were p N3.

Results: With a median follow-up time of 61 months, the 5-year cumulative rate of locoregional failure (LRF) rates and distant metastasis (DM) rates were 12% and 21%. The 5-year overall survival rates and 5-year disease free survival rates were 81% and 73% in the whole group. Univariate and multivariate demonstrated that histological grade, pathological N stage and lymph-vascular space invasion (LVSI) were independent prognostic factors associated with LRF. We deeply scored these factors and then categorized patients into 2 risk groups depend on the scoring. In low risk group, radiotherapy did not decrease LRF (3.3% in PMRT group, 1.7% in no PMRT group, p=0.192). While in high risk group, PMRT significantly decreased LRF rates (21.8% in PMRT group vs. 42.2% in no PMRT group, p=0.031).

Conclusion: Histological grade, LVSI and pathological N stage were important prognostic factors associated with LRF in breast cancer staged in cT1-2N0-1, who were managed with NAC and mastectomy, and PMRT significantly decreased LRF in high risk subgroups.

Author Disclosure: X. Wang: None. Z. Yin: None. L. Xu: None.

Send Email for Xin Wang


Assets

TU_7_3391 - Risk-Adapted Postmastectomy Radiation Therapy for Patients with Clinical T1-2N0-1 Breast Cancer after Neoadjuvant Chemotherapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Risk-Adapted Postmastectomy Radiation Therapy for Patients with Clinical T1-2N0-1 Breast Cancer after Neoadjuvant Chemotherapy